Expertise in
5
conditions

Chiung-chih Y. Chang

Kaohsiung, KHQ, TW 
Expertise in
5
conditions
Kaohsiung, KHQ, TW 
OverviewLocationsClinical Research

Overview

Chiung-chih Chang practices in Kaohsiung, Taiwan. Chang is highly rated in 5 conditions, according to our data. Their top areas of expertise are Dementia, Alzheimer's Disease, Meningitis, and Developmental Dysphasia Familial.

Their clinical research consists of co-authoring 151 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Locations

Kaohsiung, KHQ, Taiwan
Other Locations
TPQ, Taiwan
Taoyuan, TNQ 33302, Taiwan
Taipei, TNQ, Taiwan
Taitung, TNQ, Taiwan
Hsinchu, TNQ 30010, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)
An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)
Enrollment Status: Terminated
Publish Date: January 26, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 1 Less Clinical Trial

150 Total Publications

Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.
Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.
Journal: Neurology
Published: December 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chang's expertise for a condition
ConditionClose
      View All 26 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile